You're browsing HLTH 2018's website. Visit hlth.com to explore this year's edition!

Main caricature of Gregory Raskin, MD, who is speaking at HLTH and is Vice President, Technology Development at Memorial Sloan Kettering Cancer Center Overlay caricature of Gregory Raskin, MD, who is speaking at HLTH and is Vice President, Technology Development at Memorial Sloan Kettering Cancer Center

Gregory Raskin, MD

Vice President, Technology Development

Memorial Sloan Kettering Cancer Center



Dr. Greg Raskin is Vice President of Technology Development at Memorial Sloan Kettering Cancer Center (MSK), the world’s oldest and largest private cancer center. He leads efforts to bring MSK’s innovations to patients while creating value for the medical center. During his career, Greg has invested in, helped start, and licensed technology to companies in the therapeutics, diagnostics, research tools, and IT spaces. He currently serves as a director on the board of Y-mAbs Therapeutics, a privately-held, clinical-stage biotech company developing oncology drugs. He previously served as MSK’s observer on the board of Juno Therapeutics until its IPO in 2014.

Before joining MSK in 2012, Greg led healthcare and life sciences investing for AllianceBernstein’s $200 million venture capital fund. Earlier, he was a biotech analyst with Baker Brothers Investments; a management consultant to pharmaceutical companies with McKinsey; and a resident physician on the internal medicine house staff at NYU and Bellevue hospitals.

Greg earned both his medical degree and bachelor’s degree from Yale University, where he is now a Lecturer co-teaching an undergraduate course, “The Business and Science of Medicine,” on biotech and drug development. He lives in New York City with his wife and their two children.